Panagiota Economopoulou
Overview
Explore the profile of Panagiota Economopoulou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
1319
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Papanikolaou C, Economopoulou P, Gavrielatou N, Mavroeidi D, Psyrri A, Souliotis V
Biology (Basel)
. 2025 Feb;
14(2).
PMID: 40001963
Accumulation of evidence highlighted the crosstalk between DNA damage repair and the immune system. Herein, we tested the hypothesis that in head and neck squamous cell carcinoma (HNSCC), the DNA...
2.
Moutafi M, Kyriazoglou A, Kotsantis I, Economopoulou P, Efthymiou E, Kyrkasiadou M, et al.
Exp Ther Med
. 2025 Feb;
29(4):62.
PMID: 39991718
Harlequin syndrome is a rare autonomic disorder with at least 83 reported cases in literature, 6% of which are congenital. When the fibers responsible for sudomotor and vasomotor supply to...
3.
Baliga S, Abou-Foul A, Parente P, Szturz P, Thariat J, Shreenivas A, et al.
Eur J Cancer
. 2024 Apr;
203:114038.
PMID: 38579517
The Head and Neck Cancer International Group (HNCIG) has undertaken an international modified Delphi process to reach consensus on the essential data variables to be included in a minimum database...
4.
Economopoulou P, Kotsantis I, Psyrri A
Front Oncol
. 2023 Sep;
13:1278798.
PMID: 37771432
No abstract available.
5.
Moutafi M, Koliou G, Papaxoinis G, Economopoulou P, Kotsantis I, Gkotzamanidou M, et al.
Cancer Res Commun
. 2023 Aug;
3(8):1514-1523.
PMID: 37575280
Purpose: We conducted a phase II randomized noncomparative window of opportunity (WOO) trial to evaluate the inhibition of cellular proliferation and the modulation of immune microenvironment after treatment with olaparib...
6.
Strati A, Economopoulou P, Lianidou E, Psyrri A
Biomedicines
. 2023 Jun;
11(6).
PMID: 37371863
The approval of monoclonal antibodies against programmed death-ligand 1 (PD-L1) and programmed cell death protein (PD1) has changed the landscape of cancer treatment. To date, many immune checkpoint inhibitors (ICIs)...
7.
Gavrielatou N, Vathiotis I, Aung T, Shafi S, Burela S, Fernandez A, et al.
Cancer Res Commun
. 2023 Apr;
3(4):558-563.
PMID: 37057033
Significance: In the current study, DSP revealed the positive association of B2M expression in the tumor compartment with immunotherapy outcomes in R/M HNSCC.
8.
Pantazopoulos T, Leventakou D, Koufopoulos N, Pouliakis A, Economopoulou P, Glava C, et al.
Anticancer Res
. 2023 Mar;
43(4):1709-1717.
PMID: 36974793
Background/aim: Adenoid cystic carcinoma (ACC) is an aggressive neoplasm even though it has low-grade histological appearance and slow growth. The aim of this study was to identify the immunohistochemical and...
9.
Economopoulou P, Spathis A, Kotsantis I, Maratou E, Anastasiou M, Moutafi M, et al.
Oral Oncol
. 2023 Mar;
139:106358.
PMID: 36871349
Objectives: The aim of this pilot study was to evaluate the presence of somatic mutations in matched tumor and circulating DNA (ctDNA) samples from patients with primary head and neck...
10.
Mountzios G, Planchard D, Metro G, Tsiouda D, Prelaj A, Lampaki S, et al.
JTO Clin Res Rep
. 2023 Feb;
4(1):100433.
PMID: 36793384
Introduction: Real-world evidence regarding molecular epidemiology and management patterns of patients with EGFR exon-20 mutated, advanced NSCLC outside the context of clinical trials is lacking. Methods: We created a European...